[Guangshengtang: Plans to use 587 million yuan of raised funds to increase investment in its holding subsidiary to implement innovative drug research and development projects] On September 17, Guangshengtang (300436.SZ) announced that the company plans to increase its investment by 587 million yuan in its holding subsidiary Guangsheng Zhonglin, which is the main implementation entity of the fundraising project. The entire amount of this capital increase will be used to implement the "innovative drug research and development project" of the fundraising project. After the capital increase was completed, the company's shareholding ratio in Guangsheng Zhonglin changed from 75.3163% to 79.3584%, and Guangsheng Zhonglin remained a holding subsidiary of the company. This capital increase constitutes a related transaction, which still needs to be submitted to the shareholders' meeting for review.